DOJ subpoenas Aegerion over Juxtapid

Candace Stuart | | Cardiovascular Business | Structural Heart Disease

Aegerion Pharmaceuticals confirmed that it is under a federal magnifying glass again. The company disclosed in a financial statement that it was subpoenaed by the Department of Justice (DOJ) over its cholesterol drug, lomitapide.

The subpoena requested that the Cambridge, Mass.-based company provide documents about sales and marketing of lomitapide. Lomitapide (Juxtapid) has been approved as an adjunct to a low-fat diet and other treatments that lower lipids in patients with homozygous familial hypercholesterolemia.

In November 2013, Aegerion CEO Marc Beer received a warning letter from the FBI, which accused him of misbranding Juxtapid during appearances on a CNBC show “Fast Money.”

The company said it is cooperating with the DOJ in its investigation. 

Candace Stuart, Contributor

Related Content

CMS proposes Medicare coverage for transcatheter tricuspid valve replacement
Hydra TAVR valve gains key approval as global reach continues to grow
SAVR outperforms TAVR in patients with bicuspid aortic valves
Treating AFib patients with TAVR still linked to elevated risks
Heart surgeons detail world’s first robotic heart procedure of its kind
Years of progress have made TAVR more effective when treating concomitant mitral stenosis

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.